e11548 Background: Triple-negative breast cancers have an aggressive clinical history such as high incidence of visceral metastases, high rate of cerebral metastases, high rate of local recurrence, and early age of onset. However, there are limited long-term clinical data evaluating outcomes of locoregional and systemic therapy. The purpose of this study was to evaluate the clinical outcome of current therapy with TNBC retrospectively. Methods: From the medical records of our hospital, we retrospectively reviewed breast cancer patients whose three markers were available and describe the relationship between current therapy and clinical outcome. Results: Between 1998 and 2007, 1967 breast cancer patients were treated in Kumamoto City Hospital. Of 1967 patients, 264 (13.4%) were classified as TNBC by immunohistochemical technique. As of December 2008, with a median follow-up time of 31months, 53 patients (20.0%) with TNBC had locoregional recurrences or distant metastases (17 local recurrences, 15 nodal recurrences, 44 distant metastases). Forty out of 53 patients with recurrent TNBCs had adjuvant or neoadjuvant chemotherapy around surgery. Of 53 patients with recurrences, 31 had initial locoregional recurrence and 19 had initial distant metastases. Forty two patients had already been dead and common causes of death were lung metastases (19 patients), liver metastases (11 patients), and brain metastases (8 patients). Patients with TNBCs had a poorer 5 year-survival compared with those with non-TNBCs. Furthermore, patients with initial distant metastases had significantly poorer survival than those with initial locoregional recurrence (p=0.015). Focusing on chemotherapy, no specific cytotoxic agent had high effectiveness for recurrent TNBCs. However, patients who had responded to first regimens had a tendency to respond to the next regimens. Conclusions: TNBC had an aggressive behavior and poorer prognosis. However, TNBC with locoregional recurrence and benefits from the first regimen had favorable prognosis. Therefore, to distinguish the subgroup that respond to chemotherapy might contribute to the prolongation of survival of in TNBC. No significant financial relationships to disclose.
Immediate Free TRAM Flap Reconstruction after Mastectomy in Breast Cancer Patients
